Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting
Two oral presentations will highlight research related to Invea’s lead program INVA8001 and the therapeutic impact on mast cell-driven chronic inflammatory diseases
Press Releases
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
– Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology
– Company also primed to advance additional programs, including a pan-inflammasome inhibitor
Invea Therapeutics Announces Poster Presentations at Keystone Symposia Gut-Brain Axis and Digestive Disease Week (DDW2022)
Poster presentations to feature research on leveraging artificial intelligence and machine learning methods to decode the gut-brain axis, innate immunity, and neuroinflammation for target identification and drug discovery
